The phrase “hantavirus mortality rate” is meaningless without one critical qualifier: which strain? The difference between Puumala virus and Andes virus is not a matter of degree — it is a difference between a disease that kills fewer than 1 in 100 patients and one that kills nearly 4 in 10. Understanding why those numbers are so different requires looking at biology, geography, and healthcare infrastructure simultaneously.
The Global Hantavirus Mortality Landscape
HPS Strains (Hantavirus Pulmonary Syndrome) — High Mortality
These strains primarily attack the lungs and carry the highest fatality rates:
| Strain | Primary Region | Reservoir | CFR | Cases/Year (est.) |
|---|---|---|---|---|
| Andes virus (ANDV) | Argentina, Chile | Long-tailed pygmy rice rat | 35–40% | 100–150 (endemic) + 2026 cluster |
| Sin Nombre virus (SNV) | USA, Canada | Deer mouse | 36–38% | 20–40 |
| Bayou virus | USA (Gulf Coast) | Rice rat | ~35% | <5 |
| Black Creek Canal | USA (Florida) | Cotton rat | ~35% | <5 |
| Choclo virus | Panama | Pygmy rice rat | ~20% | <10 |
| Laguna Negra | Bolivia, Paraguay | Vesper mouse | ~30% | <20 |
HFRS Strains (Haemorrhagic Fever with Renal Syndrome) — Variable Mortality
These strains primarily attack the kidneys. Mortality is lower but ranges widely:
| Strain | Primary Region | Reservoir | CFR | Cases/Year (est.) |
|---|---|---|---|---|
| Hantaan virus | Korea, China, Russia | Striped field mouse | 1–15% | ~150,000 |
| Dobrava virus | Balkans, Central Europe | Yellow-necked mouse | 5–12% | ~3,000 |
| Seoul virus | Global (urban) | Brown rat | <1% | Underreported |
| Puumala virus | Europe (Scandinavia, central) | Bank vole | <1% | ~10,000–15,000 |
| Tula virus | Europe | European common vole | Very rare/mild | Sporadic |
Why Do HPS Strains Kill So Many More People Than HFRS Strains?
The answer lies in organ targeting and immunopathology.
HPS strains infect pulmonary capillary endothelial cells — the cells lining lung blood vessels. When the immune system attacks infected cells, capillary permeability surges. Fluid floods the alveoli. The patient drowns internally.
The lungs have no reserve capacity. When gas exchange fails, death comes within hours without mechanical ventilation. Even with ventilation, the immune cascade continues. Mortality remains high because the treatment — mechanical ventilation and ECMO — buys time, but cannot stop the underlying immunopathological process.
HFRS strains infect renal tubular cells and the endothelium of small blood vessels in the kidneys. The kidneys fail, but renal failure — unlike lung failure — can be managed with dialysis for days or weeks while the immune response resolves. The kidney also has more tolerance for partial function loss than the lung does.
This explains why Puumala (HFRS) kills fewer than 1% of patients while Andes (HPS) kills 35–40%.
Why Is Andes Slightly More Lethal Than Sin Nombre?
Both cause HPS, yet Andes virus carries a marginally higher CFR. Several factors contribute:
1. Healthcare infrastructure: The majority of Andes virus cases occur in rural Patagonia and southern Chile — areas with limited ICU capacity and, crucially, limited access to ECMO. Sin Nombre cases in the US are managed at facilities with better ECMO access, likely reducing CFR by 5–10 percentage points.
2. Viral virulence: Some studies suggest Andes virus replicates more efficiently in human lung tissue than Sin Nombre, though this is debated.
3. Unique P2P transmission risk: Andes virus can spread person-to-person, potentially creating chains of more vulnerable secondary cases (close contacts who are already fatigued and immunologically stressed from caring for a sick patient).
4. Case ascertainment: In remote Argentine provinces, some deaths may be attributed to “pneumonia” without hantavirus testing, potentially understating both numerator and denominator.
Puumala’s <1% Rate: What Makes It So Different?
Puumala virus is the dominant hantavirus strain across most of Europe, with endemic activity in Scandinavia, Finland, Germany, France, Belgium, and the Balkans. It causes Nephropathia Epidemica — a form of HFRS characterised by:
- Fever and backache
- Kidney dysfunction (elevated creatinine, reduced urine output)
- Thrombocytopenia and blurred vision (from retinal haemorrhage)
- Spontaneous recovery in most patients within 2–4 weeks
It almost never causes pulmonary oedema. Dialysis is required in roughly 5% of cases. The vast majority of patients are hospitalised for symptom management and kidney monitoring, then discharged fully recovered.
A European patient who hears “hantavirus” in 2026 needs to understand: the Andes virus killing people from the Hondius cruise is a fundamentally different disease from the Puumala virus that causes sporadic hospitalizations across Europe every year. They share a family name but occupy different ends of the severity spectrum.
The 2026 Hondius Cluster in Context
The MV Hondius outbreak involves Andes virus. Current data as of 13 May 2026:
- 10 confirmed cases
- 3 deaths — CFR 30%
- 7 survivors, 3 in ICU
A 30% CFR is slightly below the historical Andes virus average of 35–40%. This likely reflects the characteristics of this specific cohort: passengers from high-income countries with rapid access to tertiary care facilities and ECMO capability.
If the same cases had occurred in rural Argentina without ICU access, the fatality rate would likely be higher. This is not a commentary on Argentine healthcare — it is a reflection of the structural disadvantages of managing any critical illness in remote areas.
How CFR Has Changed Over Time
Hantavirus CFR has declined measurably since the disease was first characterised in 1993:
| Period | Sin Nombre CFR | Notes |
|---|---|---|
| 1993–1995 | ~70% | Disease newly recognised; no established protocols |
| 1996–2005 | ~45% | Growing awareness; improved ICU protocols |
| 2006–2015 | ~38% | ECMO introduced at referral centres |
| 2016–2026 | ~36% | Optimised ECMO protocols; earlier recognition |
The improvement is almost entirely attributable to earlier recognition (reducing time to ICU admission) and ECMO availability (rescuing patients who previously died from refractory shock). No new antiviral drug has driven the improvement.
For Andes virus in Argentina, CFR improvement has been slower due to the structural limitations noted above, but has also declined from historical estimates of 40–50% to approximately 35–40% in recent years.
What Determines Individual Survival?
Beyond strain and geography, these factors predict outcome:
| Factor | Effect on Survival |
|---|---|
| Early presentation (prodromal phase) | Strongly positive |
| ECMO availability | Strongly positive |
| Age 20–40 | Paradoxically, may be negative (stronger immune response = more lung damage) |
| Obesity / diabetes | Negative |
| Delayed diagnosis | Strongly negative |
| Rural location | Negative (distance to ECMO) |
The Bottom Line
The hantavirus mortality rate ranges from almost zero (Puumala in Europe) to nearly 40% (Andes and Sin Nombre in HPS patients without ECMO access). The number you see in a headline without strain context is largely meaningless.
What the data consistently shows is that the single largest modifiable risk factor is time to ICU care. The virus’s lethality is not fixed — it is substantially determined by how quickly a patient reaches appropriate treatment.
See which countries currently have active hantavirus cases on our live map →
Explore HantavirusMap